Page 29 - MemoriaEHD-Eng

www.ciberehd.org

It does this consistently in all the analyzed subgroups. In fact, it is the only syste-

mic treatment that has demonstrated anti-neoplastic activity. There is preliminary
evidence that hepatocarcinoma can be sensitive to immunotherapy strategies, in-

cluding enhancement of cytotoxic T-lymphocyte response by means of anti-CTLA-4
antibodies. In addition, antibodies targeting programmed cell death receptor type

1 (PD-1) have demonstrated considerable antitumor activity in patients with lung

tumors, kidney tumors or melanoma. The general objective of this project is to de-
termine if treatment with Nivolumab, a completely humanized monoclonal antibody

that is active against the PD-1 receptor, possesses antitumor action in patients with

advanced hepatocarcinoma.

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

29